Evidence-based coverage of weight management, GLP-1 medications, and what the clinical research shows.
20 articles
Higher protein intake during weight loss preserves muscle mass, increases satiety, and improves body composition outcomes. Here is what the controlled research shows about optimal protein on a caloric deficit.
Semaglutide and tirzepatide reduce progression from prediabetes to type 2 diabetes. Here is what the trial data shows about using GLP-1 medications before diabetes is established.
The SELECT trial found that semaglutide reduced major cardiovascular events by 20% in overweight adults with existing cardiovascular disease. Here is what the trial showed and why it matters.
Liraglutide (Saxenda) was the first GLP-1 approved for weight loss. Semaglutide produces roughly double the average weight loss. Here is what the clinical trials show about each.
Some patients combine intermittent fasting with semaglutide or tirzepatide. Here is what the limited evidence shows and what practical considerations apply when using both approaches.
BMI correlates with health risk at the population level but misclassifies millions of individuals. Here is what the research shows about its limitations and what better metrics exist.
Weight loss from semaglutide and tirzepatide includes lean muscle mass as well as fat. Here is what the trial data shows about the extent of muscle loss and what reduces it.
Tirzepatide produced higher average weight loss than semaglutide in separate trials, but the studies used different populations and protocols. Here is what the data actually supports.
Mounjaro and Zepbound contain identical tirzepatide at the same doses. The difference is the approved indication. Here is what that means for prescribing, insurance coverage, and cost.
Semaglutide can be prescribed by a primary care doctor, endocrinologist, bariatric specialist, or telehealth provider. Here is how each path works and what to expect.
Rapid weight loss from GLP-1 medications can cause facial fat loss and skin laxity. Here is what the dermatology literature shows about why it happens and what options exist.
Visceral fat wraps around internal organs and drives metabolic risk in ways subcutaneous fat does not. Here is what differentiates the two and why location determines health impact.
Semaglutide slows gastric emptying, which changes how quickly alcohol is absorbed. Some users also report reduced cravings for alcohol. Here is what the evidence shows.
Compounded semaglutide and Ozempic contain the same active molecule but differ in manufacturing, regulation, and verification. Here is what that means in practice.
Most semaglutide and tirzepatide users experience a weight loss plateau after 6-12 months. Here is the physiology behind it and the evidence on what actually helps.
Nausea affects roughly 44% of semaglutide users in clinical trials, most often during dose escalation. Here is what causes it and what the evidence shows about managing it.
Brand-name Wegovy lists at around $1,349 per month. Compounded semaglutide runs $200-500 monthly. Here is a full breakdown of what semaglutide actually costs across every option.
Ozempic and Wegovy both contain semaglutide but are approved for different conditions at different doses. Here is what the regulatory distinction means in practice for patients.
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for weight loss under the brand name Zepbound. Here is how its mechanism differs from semaglutide and what the clinical trials show.
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows digestion. Here is what the clinical evidence shows about how it works and who it is appropriate for.